个人简介

浙江大学医学院附属第一医院特聘副研究员，硕士研究生导师。博士毕业于浙江大学医学院，毕业后在浙江大学医学院从事博士后研究。2025年起加入浙江大学医学院附属第一医院任特聘副研究员。以第一作者或通讯作者身份在Leukemia、Blood Cancer Discovery、Blood Cancer Journal、Research等血液学领域国际期刊发表SCI论文10多篇。作为项目负责人，主持国家自然科学基金项目1项、中国博士后科学基金项目1项。已获授权国家发明专利3项。

研究方向

长期致力于复发难治性白血病的耐药机制研究，聚焦于探索疾病进展中的分子调控网络及信号通路异常，为克服临床耐药提供理论依据。开展针对性的靶向药物研发、新型免疫治疗策略探索及相关联合治疗方案的优化。

成果奖项：（近五年主要成果及奖励情况）

1. Yang C#, Kang YY#, Zhu CY#, Ma Y, Yu PH, Yang T, Liu YQ, Zhang ZY, Suzuki N, Ogra Y, Björklund M*, Naranmandura H*. Heat stress targets and degrades BCR::ABL1 oncoproteins to overcome drug-resistance in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2025, 39(9):2140-2151.

2. Yu PH#, Zhu CY#, Kang YY, Naranmandura H*, Yang C*. Mutation in the Unrearranged PML Allele Confers Resistance to Arsenic Trioxide in Acute Promyelocytic Leukemia. Research (Wash D C). 2025, 8:0696.

3. Zhu CY#, Yu PH#, Sun Q, Hong DF, Yang C*, Naranmandura H*. Nuclear receptors in metabolism and diseases: Mechanistic and therapeutic insights. Pharmacol Res. 2025, 218:107862.

4. Yu PH, Zhang ZY, Kang YY, Huang P, Yang C*, Naranmandura H*. Acute myeloid leukemia with t(8;21) translocation: Molecular pathogenesis, potential therapeutics and future directions. Biochem Pharmacol. 2025, 233:116774.

5. Yang T, Zhu CY, Yu PH, Yang C*, Naranmandura H*. Arsenic trioxide could promote SARS-CoV-2 NSP12 protein degradation. J Gen Virol. 2025, 106(7):002121.

6. Wang H#, Yang C#, Shi T#, Zhang Y#, Qian J, Wang Y, Hu Y, Mao L, Ye X, Liu F, Xi Z, Shou L, Fu C, Naranmandura H*, Jin J*, Zhu HH*. Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia. Blood Cancer J. 2022, 12(1):20.

7. Yang C#, Jiang Y#, Hao SH, Yan XY, Hong F, Naranmandura H*. Aptamers: an emerging navigation tool of therapeutic agents for targeted cancer therapy. J Mater Chem B. 2021,10(1):20-33..

8. Maimaitiyiming Y#, Wang QQ# Yang C#, Ogra Y, Lou Y, Smith CA, Hussain L, Shao YM, Lin J, Liu J, Wang L, Zhu Y, Lou H, Huang Y, Li X, Chang KJ, Chen H, Li H, Huang Y, Tse E, Sun J, Bu N, Chiou SH, Zhang YF, Hua HY, Ma LY, Huang P, Ge MH, Cao FL, Cheng X, Sun H, Zhou J, Vasliou V, Xu P, Jin J, Bjorklund M, Zhu HH, Hsu CH*, Naranmandura H*. Hyperthermia Selectively Destabilizes Oncogenic Fusion Proteins. Blood Cancer Discov. 2021, 2(4):388-401.

9. Ge MH#, Zhu XH#, Shao YM#, Wang C, Huang P, Wang Y, Jiang Y, Maimaitiyiming Y, Chen E, Yang C*, Naranmandura H*. Synthesis and characterization of CD133 targeted aptamer-drug conjugates for precision therapy of anaplastic thyroid cancer. Biomater Sci. 2021 Feb 23;9(4):1313-1324.

10. Yang C#, Wang Y#, Ge MH#, Fu YJ, Hao R, Islam K, Huang P, Chen F, Sun J, Hong F, Naranmandura H*. Rapid identification of specific DNA aptamers precisely targeting CD33 positive leukemia cells through a paired cell-based approach. Biomater Sci. 2019 Feb 26;7(3):938-950.

11. Yang C#, Hao R#, Lan YF, Chen YJ, Wang C, Bu N, Wang QQ, Hussain L, Ma LY, Maimaitiyiming Y, Lu XY, Naranmandura H*. Integrity of zinc finger motifs in PML protein is necessary for inducing its degradation by antimony. Metallomics. 2019, 11(8):1419-1429.

社会任职

Element期刊青年编委，Bioengineering期刊客座编辑